Greenwood Genetic Center   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Greenwood SC United States (1974)

Organization Overview

First Clinical Trial
2006
NCT00348933
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

levodopa (larodopa) (1 trial)

Drugs in Phase 2 Trials (1)

nnz2566 (2 trials)

Drugs in Other Trials (4)

betaine (1 trial)

creatine (1 trial)

cyanocobalamin (berocca) (1 trial)

methylfolate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angelman Syndrome (Phase 3)

Fragile X Syndrome (Phase 2)

Rett Syndrome (Phase 2)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 6